Discriminatory Formulary Language In HHS Proposal Brings Deluge Of Conflicting Comments
Executive Summary
HHS statements in a recent proposed rule identifying specific Affordable Care Act plan formulary practices as discriminatory elicit strong debate from insurance regulators, payers, patient advocates and pharma companies.